Nanjing Medlander Medical Technology (SH:688273)2026-02-26 08:15Financial Performance - Total revenue for 2025 reached CNY 431.59 million, a year-on-year increase of 1.66%[4] - Operating profit decreased to CNY 104.69 million, down 8.53% compared to the previous year[4] - Total profit fell to CNY 104.29 million, a decline of 16.65% year-on-year[4] - Net profit attributable to shareholders of the parent company was CNY 102.06 million, up 0.47% from the previous year[4] - Net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 80.10 million, down 2.32% year-on-year[4] - Basic earnings per share increased to CNY 1.0434, a rise of 1.21% year-on-year[4] Assets and Equity - Total assets at the end of the reporting period were CNY 1,557.58 million, an increase of 0.71% from the beginning of the period[4] - Equity attributable to shareholders of the parent company rose to CNY 1,347.25 million, up 2.67% from the beginning of the period[4] Business Development - The company continued to strengthen brand building and channel optimization to support business development[7] - The reproductive rehabilitation product line maintained a solid advantage in its niche market, achieving steady growth[7]